Advanced searches left 3/3

Levofloxacin - Europe PMC

Summarized by Plex Scholar
Last Updated: 08 June 2022

* If you want to update the article please login/register

Levofloxacin versus clarithromycin for Helicobacter pylori eradication: are 14 day regimens better than 10 day regimens?

"Methods Patients with H. pylori infection were diagnosed with H. pylori disease and treated with levofloxacin triple therapy or clarithromycin-based regimen for ten or 14 days were included," Methods Patients with H. pylori infection and treated with levofloxacin triple therapy or clarithromycin-based therapy for ten or 14 days were included. Patients were not allowed to use antibiotics or proton pump inhibitors within 4 or 2 weeks of the H. pylori eradication confirmation test, respectively. About 245 patients, 145 in the levofloxacin group and 100 in the clarithromycin group were out of the clarithromycin group. The majority of patients in either group received medication for 14 days vs. ten days. Compared to clarithromycin-based therapy, Levofloxacin-based therapy was associated with a higher eradication rate. The H. pylori eradication was not influenced by diabetes or EGD findings, nor were there any implications of diabetes or EGD findings. Despite diabetes and EGD results, the results from this research show that the use of a levofloxacin-based regimen as a first-line therapy in the treatment of H. pylori infection for 14 days. ".

Source link: https://europepmc.org/article/MED/35668511


In-stream sorption of azithromycin and levofloxacin in a river receiving sewage treatment plant effluent.

"The average distribution coefficients for dissolved and particulate phases in the outflow river water were 6. 3 kg and 7. 10 L/kg for LVF, while those in the STP effluent were 1-2 orders of magnitude lower. " MB w MB w a MB is credited to an increase in suspended particulate matter -mediated mass flows in the river stretch, i. e. , in-stream sorption to SPM, which was largely due to their much higher river K d,SPM values than those in the effluent. Their river K d,SPM values increased on higher-flow days with decreasing effluent content in the river water, leading to an increase in in-stream SPM sorption. AZM and LVF were mostly in the river stretch during the dissolved phase of STP effluent's degradation phase, particularly on high-flow days, according to a key finding.

Source link: https://europepmc.org/article/MED/35661806


Subinhibitory Cefotaxime and Levofloxacin Concentrations Contribute to Selection of Pseudomonas aeruginosa in Coculture with Staphylococcus aureus.

Both Pseudomonas aeruginosa and Staphylococcus aureus are two common bacterial pathogens that are often coisolated from patients with burns and respiratory disease. " P. aeruginosa in coculture, a subinhibitory concentration of cefotaxime helps with S. autum growth suppression. This process may be related to the increased manufacturing of the antistaphylococcal molecule pyocyanin and the expression of lasR, the central regulatory gene of P. aeruginosa QS' hierarchy. On the other hand, subinhibitory concentrations of levofloxacin reduce P. aeruginosa's competitive advantage over S. auricus by stymieing expansion and the P. aeruginosa's las QS system. To beat S. aupus, a P. aeruginosa's warning can be activated instead. This research contributes to knowing the interactivity of P. aeruginosa and S. aureus during antibiotic therapy, as well as providing a solid basis for investigating polymicrobial infections' pathogenesis. We looked at the correlation of cocultured P. aeruginosa and S. aureus with the use of commonly used antibiotics in clinics. We found that applying subinhibitory concentrations of cefotaxime and levofloxacin can select P. aeruginosa in coculture with S. aurus by changing P. aeruginosa QS law to increase the production of antistaphylococcal metabolites in a variety of ways. This paper discusses the role of the QS system in the proliferation of P. aeruginosa in the interaction of P. aeruginosa with other bacterial species as well as a source for further clinical therapy.

Source link: https://europepmc.org/article/MED/35638844


Population pharmacokinetics and dose optimization of intravenous levofloxacin in hospitalized adult patients.

"While levofloxacin has been used for over 25 years, there are no pharmacokinetic studies to support levofloxacin dosing in adult patients. " This research was designed to produce a population pharmacokinetic model of levofloxacin in adult hospitalized patients and identify dosing regimens that meet a target pharmacokinetic/pharmacodynamic target with maximum success. Microbiotics with MIC u2265 1 mg/L were found in an area under free concentration curve to MIC u2265 80 was barely achievable for pathogens with MIC u2265 1 mg/L. Patients with elevated eGFR were seen with Low FTA against Pseudomonas aeruginosa and Streptococcus pneumoniae.

Source link: https://europepmc.org/article/MED/35624222


Intracellular Activity of Poly (DL-lactide-co-glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid or Ethambutol on Multidrug-Resistant Mycobacterium Tuberculosis.

"Background Multidrug-resistant Mycobacterium tuberculosis is a common cause of death amongst tuberculosis patients. " Similarly, the effect of anti-TB drug nanoparticle compounds in anti-TB regimens against MDR-TB remains unclear. Methods The multiple emulsion technique yielded drug-loaded PLGA NPs. Conclusions All drug-loaded PLGA NPs were spherical in shape, from 150 to 210 nm in length, and showed 14. 22% to 43. 5 percent encapsulation yields and long-duration release. The number of colonies after exposure to PLGA NP compounds was considerably smaller than those that were free drug products. The increased antibacterial activity of the NP compounds may be due to the enhanced levels of ROS and NO, as well as the increased early apoptosis strain in M. tuberculosis-infected macrophages. Conclusions The use of PLGA NP compounds not only improves drug stability but also triggers inherent bactericidal activity in macrophages, confirming this as a promising treatment for MDR-TB therapy. ".

Source link: https://europepmc.org/article/MED/35546770

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions